137 results about "Lipid particle" patented technology

The instant disclosure relates to lipid particles that harbor cationic lipids, the particles found to be capable of delivering associated cargoes - particularly nucleic acid cargoes when formulated as nucleic acid-lipid particles - intracellularly to skin tissue cells when administered topically to a subject. The instant disclosure provides compositions comprising such lipid particles, optionally in association with a therapeutic agent (e.g., a therapeutic mRNA and / or nucleic acid controller system), as well as methods and kits for delivering a lipid particle-associated therapeutic agent and / or for treating or preventing a disease or disorder, e.g., a skin disease or disorder, in a subject, using one or more lipid particle compositions provided herein.

Certain embodiments of the invention provide a cationic lipid of formula (I):wherein R1, R2, R3 and R4 are defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and / or administering the lipid particles.

Disclosed herein are a peptoid compound and a peptoid conjugate such as a peptoid-lipid conjugate, and preparation methods therefor and the use thereof in a small molecule drug and nucleic acid delivery. Further disclosed herein are a lipid particle containing the peptoid-lipid conjugate, such as a liposome and a lipid nanoparticle, and a small molecule drug and / or a nucleic acid delivery composition containing the peptoid-lipid conjugate or the lipid particle. The peptoid-lipid conjugate, lipid particle, and small molecule drug and / or nucleic acid delivery composition that can be used for the small molecule drug and nucleic acid delivery of the present invention enable highly efficient compounding, protection, intracellular and targeted delivery and release of the small molecule drug and biomolecules, such as nucleic acids, in tissues and organs both in vitro and in vivo.

The invention discloses a multilevel liver targeting drug delivery system based on ionizable amino lipid and a preparation method thereof, the system comprises the following components: target modified ionizable amino lipid, ionizable amino lipid, auxiliary lipid and structural lipid in a molar ratio of (10-30): (30-60): (5-40): (15-55), according to the system, nano lipid particles exist in a water-in-oil-in-water nano emulsion form; wherein the ionizable ammonia lipid is a compound with a structure as shown in a formula (I). The system is suitable for delivering nucleic acid, protein and other active pharmaceutical ingredients to the liver so as to improve the accuracy and treatment effect of drug delivery and reduce the side effects of non-target organs.

The present disclosure relates to a hydrogel ink comprising a lipid particle, a polynucleotide supported within the lipid particle, and a bio-ink. In one embodiment, the lipid particles comprise extracellular vesicles. The disclosure also relates to hydrogels thereof and their use in treating neurological diseases or conditions or regenerating soft tissue.

The invention relates to a QS-21 loaded nano adjuvant as well as a preparation method and application thereof. According to the nano adjuvant, the biodegradable polymer, cholesterol and cationic lipid entrapped QS-21 are utilized to form solid lipid particles in an O / W mode, the solid lipid particles have good dispersity, the surfaces of the solid lipid particles are positively charged, and the solid lipid particles can adsorb negatively charged antigen protein to prepare a nano adjuvant vaccine. The cholesterol in the nano adjuvant vaccine can be combined with the QS-21, so that entrapment of the QS-21 can be better realized, the safety and the stability of the nano adjuvant vaccine are improved, and the nano adjuvant vaccine has a wide application prospect in prevention of virus infection.

Disclosed herein are complex lipid particles encapsulating one or more exogenous peptides, polypeptides, or proteins, as well as methods of producing a complex lipid formulation comprising an exogenous peptide, polypeptide, or protein. Also, disclosed herein are modified plant messenger packs (PMPs) formulation encapsulating one or more exogenous peptides, polypeptides, or proteins, and methods of producing a modified PMP formulation comprising an exogenous peptide, polypeptide, or protein.

The present invention relates to compositions comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of the nucleic acid in a lipid bilayer. The present invention further relates to said compositions for use in preventing and / or treating disease, particularly for use in preventing and / or treating cancer. The present invention further relates to methods for producing compositions comprising said nucleic acid-lipid particles.

Disclosed herein are compositions for use in a variety of agricultural methods, the compositions comprising a plurality of naturally derived lipid particles comprising a phospholipid, a non-polar lipid, and a surface modifier, and further comprising a biologically active substance.

The present disclosure relates to a novel drug delivery system, which comprises a lipid particle and a modified red blood cell. The present disclosure also relates to preparation of the drug delivery system and therapeutic use thereof.

A prediction device (100) comprises: an information acquisition unit (102) that acquires a condition for preparing lipid particles that are composed of any of a phospholipid, an anionic lipid, and a cationic lipid, and a constituent lipid of the lipid particles; a trained model (103) that predicts the particle size distribution of the lipid particles from the acquired condition for preparing the lipid particles and the acquired constituent lipid of the lipid particles; and an output unit (104) that outputs the particle size distribution of the lipid particles predicted by the trained model (103).

The present disclosure provides compositions capable of delivering a load (including therapeutic agents, e.g., RNA) to organs or tissues other than the liver, lung and spleen (e.g., brain, heart, kidney and muscular tissue). More specifically, the composition comprises a plurality of lipid particles comprising an agent, a cationic lipid, and an ionizable lipid.

The present disclosure provides lipid nanoparticles that are beneficially effective in the targeting of hepatic stellate cells with enhanced specificity. The lipid nanoparticles include five lipid components, including a permanently charged cationic lipid that is a quaternary ammonium lipid. The disclosure also provides pharmaceutical compositions and methods including the provided lipid nanoparticles.

The present disclosure provides lipid nanoparticles that are beneficially effective in the targeting of hepatic stellate cells with enhanced specificity. The lipid nanoparticles include five lipid components, including a permanently charged cationic lipid that is a quaternary ammonium lipid. The disclosure also provides pharmaceutical compositions and methods including the provided lipid nanoparticles.

An aqueous dispersion having an aqueous mobile phase and a dispersed phase is described wherein: the dispersed phase comprises a lipid mixture comprising a cationically ionizable lipid; and the aqueous mobile phase comprises a buffer solution having a pH of from about 6.5 to about 8; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents, and nucleic acids. Methods of making the aqueous dispersions, nucleic acid-lipid particles, methods of making them using the aqueous dispersions, and their use in medicine are disclosed.

To provide a technique for delivering an active substance to the surface of a target cell.SOLUTION: According to one embodiment, a particle-bound lipid particle includes a biodegradable lipid particle, a particle, and active substances, wherein the particle is bound to an outer surface of the lipid particle, and the active substances are bound to a surface of the particle.SELECTED DRAWING: Figure 1

The invention discloses nucleotide of fusion protein for coding neutrophil elastase and application of the nucleotide. A nucleotide sequence for coding the fusion protein is as shown in SEQ ID NO. 8; the nucleotide sequence of mRNA (messenger ribonucleic acid) for coding the fusion protein is as shown in SEQ ID NO. 12; the fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment. The mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the wild type ELANE can achieve a tumor elimination effect only by complex intratumor injection. According to the mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the ELANE fusion protein, tumor elimination in a mouse body can be realized only through intramuscular injection administration, the operation is simpler and more convenient, and the mRNA preparation is beneficial to treatment of scattered and tiny tumor focuses in the body.

This invention belongs to the field of nanocarrier and immunotherapy technology, specifically relating to a lipid nanoparticle targeting tumor-associated macrophages, a combined delivery method, and its application in tumor immunotherapy. The lipid nanoparticles targeting CD206 tumor-associated macrophages constructed in this invention are used for efficient in vivo delivery of multifunctional nucleic acid molecules, achieving immune regulation, gene editing, and anti-tumor therapy. This invention achieves targeted delivery and multifunctional synergistic effects through lipid particle design, nucleic acid sequence design, and in vitro and in vivo functional verification. Through in vivo delivery of ipLNPs, macrophages can simultaneously achieve: 1) expression of anti-PD-L1 antibodies, blocking immunosuppressive signals; 2) expression of HER2-CAR structures, enhancing phagocytosis and killing ability against tumors; and 3) remodeling of the tumor immune microenvironment through CRISPR / Cas9-mediated FN1 knockout. The lipid nanoparticles constructed using this invention can solve the problem of insufficient targeting of immune cells in the tumor microenvironment by traditional LNP delivery systems.

According to one embodiment, there is provided a method of producing a gene modification T cell (CAR-T cells) which expresses a chimeric antigen receptor (CAR). This method includes stimulating a cell population containing a T cell with an antibody which activates the T cell, bringing the cell population into contact with a nucleic acid-introducing carrier, wherein the nucleic acid-introducing carrier containing a lipid particle, a first nucleic acid and containing a CAR gene, and a second nucleic acid containing a transposase gene encapsulated in the lipid particle, and culturing the cell population after the contacting.

The problem to be solved by the present invention is to provide cationic lipids for oligonucleotide delivery which can provide a high drug: lipid ratio, which protect the nucleic acid from degradation and clearance in serum, which are suitable for systemic delivery, which can result in intracellular delivery of the nucleic acid, and which are well tolerated, provide an adequate therapeutic index, and treatment of patients with an effective dose of the nucleic acid is not associated with significant toxicity and / or risk to the patient.SOLUTION: The present invention relates to cationic lipids having one or more biodegradable groups located in the lipid portion (e.g., hydrophobic chain) of the cationic lipid. These cationic lipids can be incorporated into lipid particles for the delivery of active agents such as nucleic acids. The present invention also relates to a lipid particle comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the invention and optionally a sterol. The lipid particles may further comprise a therapeutic agent, such as a nucleic acid.SELECTED DRAWING: None

To provide a composition for cosmetic including ceramide-containing lipid particles which is excellent in dispersion stability and use feeling.SOLUTION: A composition for cosmetic including ceramide-containing lipid particles which contains phospholipid, cholesterol, lysophospholipid and ceramide, has a volume average particle diameter of 10nm or more and 600nm or less, and polydispersity of 0.50 or less.SELECTED DRAWING: None

According to one embodiment, a substance delivery carrier and a composition are used for delivering an intended substance to a myeloid tumor cell. The substance delivery carrier has a lipid particle, and an intended substance encapsulated in the lipid particle. The lipid particle contains, as a constituent thereof, at least a first lipid represented by formula (I).

The present invention relates to a bone marrow fluid analysis method, a sample analysis device, and a recording medium containing a program. The present invention provides a means for obtaining an index related to bone marrow nucleated cell density by measuring nucleated cells and lipid particles in bone marrow fluid. By counting the number of nucleated cells and lipid particles in bone marrow fluid and obtaining an index related to bone marrow nucleated cell density based on the nucleated cell and lipid particle counts, the aforementioned technical problems are solved.

Embodiments of the present disclosure generally relate to a new class of compositions that include VZV IE62 or a derivative thereof (e.g., a mutant) and lipid particles. Embodiments of the present disclosure also relate to uses of the compositions for treating, alleviating, or reducing the severity of, various diseases or medical conditions in a patient. For example, embodiments described herein may be utilized for treating, alleviating, or reducing the severity of various neuroinflammation and related pathologies and diseases such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, neuromyelitis optica, or dementia, among others.

Disclosed are compositions comprising lipid particles and self-replicating RNA molecules and methods of treatment with the compositions.

Provided is a lipid particle which includes a drug and enables more efficient development of the function of the drug in cells. The lipid particle contains, in the polar head thereof, a modified ionized lipid having a disulfide unit and / or a modified polynucleotide having a disulfide unit.